Memorial Sloan Kettering Cancer Center (MSK) and the Tisch Cancer Institute at Mount Sinai researchers developed an artificial intelligence tool that could help cancer patients and their doctors worldwide.
According to an announcement from MSK, the tool, SCORPIO, uses “only routine blood tests and clinical data” to project if certain cancer patients “will benefit from immune checkpoint inhibitors.”
A study demonstrating how SCORPIO fares against Food and Drug Administration approved biomarkers was published January 6 in Nature Medicine.
